RCS - ReNeuron Group plc - Positive Exosome data presented at US conference

ReNeuronAnnouncement

07/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221007:nRSG0941Ca&default-theme=true

RNS Number : 0941C  ReNeuron Group plc  07 October 2022

 
ReNeuron Group plc

("ReNeuron" or the "Company")

 

Positive Exosome data presented at US conference

 

ReNeuron presents new data on the significant advantages of its stem cell
derived exosome platform, CustomEx(TM), including a 600% increase in delivery
of siRNA compared to a conventional HEK exosome approach

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived
exosomes technologies, announces that the Company's CSO, Dr Randolph
Corteling, has presented new data at the Extracellular Vesicle-Based
Therapeutic Development Summit in Boston, MA, highlighting the significant
advantages of the Company's stem cell derived exosome approach.

 

Key highlights from the presentation entitled Targeted Delivery of Therapeutic
Payloads Using Engineered Stem Cell Exosome included:

 

·    When comparing the uptake of a panel of exosomes into three different
target cell types (Epithelial cells, Endothelial cells and Neural cells),
ReNeuron identified one or more CustomEx(TM) exosome types that outperformed
the conventional approach of using human embryonic kidney-derived (HEK)
exosomes by a minimum of a 10-fold in each of the three different cell types.
This was most pronounced with Endothelial cells where one of ReNeuron's
CustomEx(TM) exosome types showed an 18-fold improvement in uptake over
HEK-derived exosomes.

·    When ReNeuron's exosomes were loaded with an siRNA payload, this
improvement in uptake was reflected in the siRNA delivery to the target cell,
with the best performing CustomEx(TM) exosome type showing a 600% improvement
in siRNA delivery to the target cell when compared to delivery from a
HEK-derived exosomes.

 

Data was also presented at the conference on the Company's continued work in
delivery of Brain Derived Neurotrophic Factor (BDNF) through the use of
exosomes. Following data presented in October 2021, the Company has now shown
in an in-vitro study in retinal ganglion cells a sustained survival rate of
these cells when treated with BDNF loaded exosomes compared to unloaded
exosomes. BDNF is known to be associated with retinal as well as neurological
degenerative processes and this data highlights the further potential of
effective delivery of BDNF in this area. Further in-vitro / in-vivo studies
assessing the potential of delivery of BDNF via exosomes are ongoing.

 

Dr Randolph Corteling, Chief Scientific Officer, commented: "This represents a
significant advance in the potential use of human stem cell-derived exosomes
as delivery vectors for complex drug modalities, with this new data
highlighting the significant improvement in uptake and delivery of a payload
that can be achieved by customising the exosome type to maximise payload
delivery to the desired cell type.

 

"ReNeuron's CustomEx(TM) platform is the only platform that offers this
ability to customise the exosome cell type for a partners' need and the
payload / target cell of their choice, while offering a scalable and
repeatable manufacturing process due to its patented conditional
immortalisation technology. This technology was enabled through the Company's
earlier work in producing GMP stem cells approved by the FDA and MHRA for the
clinic from which the Company's exosomes are now produced.

 

"I am also pleased to see positive data with our BDNF loaded exosomes
highlighting the further potential of this programme."

 

Catherine Isted, Chief Executive Officer, commented: "The key to the challenge
of drug delivery is about getting the chosen payload to the target cell of
choice. This data clearly shows how our customisable Exosomes platform
CustomEx(TM), is able to be an enabler for this exciting next generation of
targeted therapies. Our collaborations with global pharma, biotech and
academic partners already use ReNeuron's exosomes as a delivery vehicle for
their therapeutic agents, and this new data will support our efforts to
progress and increase the number of our partner programmes, a key aspect of
our monetisation strategy."

 

The presentation and a poster presented at the conference will be available
shortly on the Company's website:
https://www.reneuron.com/investors/presentations/
(https://www.reneuron.com/investors/presentations/)

 

CustomEx(TM) is a register trademark of ReNeuron Limited

 

 
ENDS

 

Contacts:

 

 ReNeuron                                      www.reneuron.com/investors (http://www.reneuron.com/investors)
 Catherine Isted, Chief Executive Officer      Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Walbrook PR (Media & Investor Relations)      +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Paul McManus / Alice Woodings                 +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABIBDGDDGDGDL